Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracie Overbeck

Allergy & Immunology Lexington, KY Medical Doctor

NPI 1881658805 CMS profile 85073

166 Pasadena Drive Suite 150, Lexington, KY 40503

Open in the dashboard

General payments

$19,230

724 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,659 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Tracie Overbeck of Lexington, KY is reported in the CMS Open Payments database as having received $19,230 across 724 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,659 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,958 135
2024 General $2,143 80
2023 General $1,947 74
2022 General $2,068 117
2021 General $1,759 98
2020 General $3,056 88
2019 General $5,300 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracie Overbeck
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Tracie Overbeck were reported at $2,958. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Tracie Overbeck Allergy & Immunology median Middle half National median
2019 $5,300 $594 $163–$1,512 $163
2020 $3,056 $426 $106–$1,233 $114
2021 $1,759 $638 $157–$1,708 $132
2022 $2,068 $790 $205–$1,961 $149
2023 $1,947 $852 $220–$2,147 $160
2024 $2,143 $865 $203–$2,267 $164
2025 $2,958 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $3,539 96 payments
  2. BioCryst Pharmaceuticals, Inc. $2,691 11 payments
  3. AstraZeneca Pharmaceuticals LP $2,360 90 payments
  4. Genzyme Corporation $1,935 77 payments
  5. GlaxoSmithKline, LLC. $1,099 61 payments
  6. Genentech USA, Inc. $740 30 payments
  7. Pharming Healthcare, Inc. $614 25 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $604 27 payments
  9. Pfizer Inc. $562 46 payments
  10. Regeneron Healthcare Solutions, Inc. $476 18 payments
  11. Other $4,611 243 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,176 711 payments
  2. Honoraria $3,500 2 payments
  3. Travel and Lodging $345 3 payments
  4. Education $196 7 payments
  5. Consulting Fee $13 1 payment
Products named General payments · program years 2019–2025
  1. Haegarda $2,369 48 payments
  2. DUPIXENT Immunology $2,097 98 payments
  3. Hizentra $1,013 41 payments
  4. Xolair $792 32 payments
  5. FASENRA $674 28 payments
  6. RUCONEST $614 25 payments
  7. NUCALA $588 30 payments
  8. TEZSPIRE Respiratory $505 6 payments
  9. TEZSPIRE Inflammation $437 29 payments
  10. DUPIXENT Inflammation And Immunology $419 15 payments
  11. Other $8,372 438 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

942

Median for Allergy/ Immunology: 449

Drug cost

$1,490,351

Median for Allergy/ Immunology: $169,700

Branded share of claims

31.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 11 $525,560
Haegarda C1 Esterase Inhibitor Brand 22 $507,341
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $122,676
Dupixent Syringe Dupilumab Brand 25 $110,628
Icatibant Icatibant Acetate Brand 15 $96,377
Dupixent Pen Dupilumab Brand 12 $46,779
Spiriva Respimat Tiotropium Bromide Brand 15 $15,148
Symbicort Budesonide/Formoterol Fumarate Brand 31 $14,888
Breo Ellipta Fluticasone/Vilanterol Brand 14 $9,329
Dulera Mometasone/Formoterol Brand 18 $9,237

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$181,518

Medicare's payments for the services billed

Medicare patients

201

Average age 71

Services billed

9,913

130 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 52%
Diabetes 23%
Ischemic heart disease 18%
Cancer 17%
Depression 17%
Osteoporosis 15%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $314
$314 37 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $127
  • Amgen Inc. $115
$242 — —
Haegarda
  • CSL Behring $218
$218 22 —
Xolair
  • Genentech USA, Inc. $170
  • Genentech, Inc. $37
$207 — —
NUCALA
  • GlaxoSmithKline, LLC. $182
$182 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

724 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record